Upstream Bio (NASDAQ:UPB) Issues Earnings Results, Misses Expectations By $0.02 EPS

Upstream Bio (NASDAQ:UPB) posted its quarterly earnings data on Wednesday. The company reported ($0.75) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.73) by ($0.02), reports. Upstream Bio had a negative return on equity of 41.73% and a negative net margin of 4,718.96%.The company had revenue of $1.03 million for the quarter, compared to analysts’ expectations of $1.03 million.

Upstream Bio Trading Down 6.1%

UPB stock opened at $8.79 on Friday. The firm has a 50 day moving average of $9.23 and a 200-day moving average of $19.27. Upstream Bio has a 12 month low of $7.25 and a 12 month high of $33.68. The firm has a market capitalization of $478.35 million, a P/E ratio of -3.02 and a beta of 1.28.

Hedge Funds Weigh In On Upstream Bio

A number of large investors have recently modified their holdings of the company. Vanguard Group Inc. boosted its position in shares of Upstream Bio by 12.5% in the third quarter. Vanguard Group Inc. now owns 2,442,551 shares of the company’s stock valued at $45,944,000 after acquiring an additional 271,718 shares during the period. Janus Henderson Group PLC bought a new position in shares of Upstream Bio in the fourth quarter valued at approximately $41,423,000. State Street Corp boosted its position in shares of Upstream Bio by 18.4% in the fourth quarter. State Street Corp now owns 1,319,226 shares of the company’s stock valued at $35,817,000 after acquiring an additional 204,645 shares during the period. Marshall Wace LLP boosted its position in shares of Upstream Bio by 198.8% in the third quarter. Marshall Wace LLP now owns 867,999 shares of the company’s stock valued at $16,327,000 after acquiring an additional 577,473 shares during the period. Finally, Geode Capital Management LLC boosted its position in shares of Upstream Bio by 4.3% in the fourth quarter. Geode Capital Management LLC now owns 851,908 shares of the company’s stock valued at $23,134,000 after acquiring an additional 34,799 shares during the period.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on the stock. Wall Street Zen downgraded shares of Upstream Bio from a “hold” rating to a “sell” rating in a report on Saturday, March 28th. Mizuho cut their target price on shares of Upstream Bio from $51.00 to $50.00 and set an “outperform” rating for the company in a research report on Thursday. Evercore lowered shares of Upstream Bio from an “outperform” rating to an “in-line” rating and set a $15.00 target price for the company. in a research report on Friday, March 27th. Finally, Weiss Ratings lowered shares of Upstream Bio from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, May 6th. Three research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $38.75.

About Upstream Bio

Upstream Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation prophylactic vaccines and immuno-oncology therapies. Leveraging a proprietary viral vector platform, the company aims to deliver optimized antigen payloads that stimulate robust and durable immune responses against both infectious diseases and cancer targets. Upstream Bio’s approach emphasizes safety, manufacturability and potential for rapid scale-up to address emerging public health challenges.

The company’s research and development pipeline includes multiple viral vector-based candidates in early clinical and preclinical stages.